Propofol has both enhancing and suppressing effects on human platelet aggregation in vitro

Area of Science:

• Anesthesiology and Pharmacology
• Biochemistry and Molecular Biology
• Hematology

Background:

• Volatile anesthetics are known to inhibit platelet aggregation.
• Conflicting data exists on propofol's effects on platelet function.
• This study investigates propofol's impact on platelet aggregation and its underlying mechanisms.

Purpose of the Study:

• To clarify the effects of propofol on platelet aggregation.
• To elucidate the mechanisms by which propofol affects platelet function.
• To reconcile conflicting findings regarding propofol and platelet aggregation.

Main Methods:

• Platelet aggregation was measured using an aggregometer with various agonists (epinephrine, arachidonic acid, prostaglandin G2, STA2).
• Cyclooxygenase-1 activity was assessed by measuring malonaldehyde formation.
• Thromboxane A2 (TXA2) formation, TXA2 receptor binding, and inositol 1,4,5-triphosphate formation were quantified.

Main Results:

• Propofol exhibited dose-dependent effects on platelet aggregation, enhancing at 40 microM and suppressing at 100 microM.
• High concentrations of propofol (100 microM) suppressed arachidonic acid-induced TXA2 formation and cyclooxygenase-1 activity.
• Propofol augmented inositol 1,4,5-triphosphate formation in STA2-stimulated platelets, indicating effects on intracellular signaling.

Conclusions:

• High propofol concentrations inhibit cyclooxygenase-1 activity, impacting platelet aggregation.
• Propofol's modulation of intracellular signaling pathways (inositol triphosphate) contributes to its complex effects on platelets.
• These findings provide a mechanistic explanation for previously inconsistent results on propofol's antiplatelet effects.